Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial

View ORCID ProfilePedro Gutiérrez-Castrellón, Tania Gandara-Martí, Ana Teresa Abreu, Cesar D. Nieto-Rufino, Eduardo López-Orduña, Irma Jiménez-Escobar, Carlos Jiménez-Gutiérrez, Gabriel López-Velazquez, View ORCID ProfileJordi Espadaler-Mazo
doi: https://doi.org/10.1101/2021.05.20.21256954
Pedro Gutiérrez-Castrellón
1Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez. Calz. De Tlalpan 4800, 14080 Ciudad de México, (CDMX), México
2International Scientific Council for Probiotics, Tenango 22, 14340, Ciudad de México, (CDMX), México
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pedro Gutiérrez-Castrellón
Tania Gandara-Martí
1Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez. Calz. De Tlalpan 4800, 14080 Ciudad de México, (CDMX), México
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Teresa Abreu
3Hospital Angeles Pedregal, Camino de Sta. Teresa 1055-S, 10700, Ciudad de México, (CDMX), México
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cesar D. Nieto-Rufino
1Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez. Calz. De Tlalpan 4800, 14080 Ciudad de México, (CDMX), México
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduardo López-Orduña
4DiagnoMol SA de CV. Camino Sta. Teresa No 13, 14110 Ciudad de México (CDMX), México
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irma Jiménez-Escobar
1Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez. Calz. De Tlalpan 4800, 14080 Ciudad de México, (CDMX), México
MHM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Jiménez-Gutiérrez
1Centro de Investigación Translacional en Ciencias de la Salud, Hospital General Dr. Manuel Gea Gonzalez. Calz. De Tlalpan 4800, 14080 Ciudad de México, (CDMX), México
DPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel López-Velazquez
2International Scientific Council for Probiotics, Tenango 22, 14340, Ciudad de México, (CDMX), México
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Espadaler-Mazo
5AB-Biotics SA (KANEKA Group), R&D Department, Av. De Torre Blanca 57, 08172 Sant Cugat, (Barcelona), Spain
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jordi Espadaler-Mazo
  • For correspondence: espadaler@ab-biotics.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Probiotics have been proposed as adjuvants for Coronavirus Disease 2019 (Covid19) but randomized controlled trials (RCT) are lacking.

Methods Single-center, quadruple-blinded RCT. Symptomatic Covid 19 outpatients (aged 18 to 60 years) with positive SARS-CoV2 nucleic acids test were randomized to active (n=150; ≥2×109 colony-forming units (CFU) of probiotic strains Lactiplantibacillus plantarum KABP022, KABP023 and KAPB033, plus strain Pediococcus acidilactici KABP021) or placebo (n=150), take orally once daily for 30 days. Oral acetaminophen was allowed and controlled as co-intervention. Primary endpoint included: i) proportion of patients in complete remission (both symptoms and nucleic acids test) or progressing to moderate or severe disease with hospitalization; ii) death rate and duration on Intensive Care Unit (ICU). Safety was assessed in all patients. This study is registered at ClinicalTrials.gov (NCT04517422).

Findings 300 subjects were randomized (median age 37.0 years [range 18 to 60], 161 [53.7%] women, 126 [42.0%] having known metabolic risk factors), and 293 completed the study (97.7%). Remission was achieved by 78 of 147 (53.1%) in the active group compared to 41 of 146 (28.1%) in placebo (P<0.0001; ARR=25.0% [95%CI 14.1-35.9%]), still significant after multiplicity correction for the primary endpoint. No hospitalizations or deaths occurred during the study, precluding the assessment of efficacy on these endpoints. No serious adverse events occurred during the study. Replication studies with this probiotic formula are warranted.

Competing Interest Statement

JEM is a full-time scientist with no stock options at Kaneka AB-Biotics SA (Barcelona, Spain), the company which provided the probiotic used in this study. ATAA reports receiving speaker fees from Kaneka AB-Biotics SA, BioGaia (Stockholm, Sweden) and Mayoly-Spindler (Chatou, France). PGC reports receiving speaker and consulting fees from BioGaia (Stockholm, Sweden). All other authors report their institution was supported by Kaneka AB-BIOTICS SA for the submitted work but have no additional competing interests. All authors have completed the ICMJE uniform disclosure form. All the authors and Kaneka AB-BIOTICS SA vouch for the accuracy and completeness of the data.

Clinical Trial

NCT04517422

Funding Statement

This study was funded by AB-Biotics S.A (Barcelona, Spain), a member of the KANEKA Group (Japan).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the Research Ethics Committee of Hospital General Dr. Manuel Gea Conzalez of Mexico City (approval number 12-120-2020

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Deidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan. To make a request, please contact the corresponding author (espadaler{at}ab-biotics.com). Decision to make IPD publicly available was taken after initial trial registration.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 24, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial
Pedro Gutiérrez-Castrellón, Tania Gandara-Martí, Ana Teresa Abreu, Cesar D. Nieto-Rufino, Eduardo López-Orduña, Irma Jiménez-Escobar, Carlos Jiménez-Gutiérrez, Gabriel López-Velazquez, Jordi Espadaler-Mazo
medRxiv 2021.05.20.21256954; doi: https://doi.org/10.1101/2021.05.20.21256954
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial
Pedro Gutiérrez-Castrellón, Tania Gandara-Martí, Ana Teresa Abreu, Cesar D. Nieto-Rufino, Eduardo López-Orduña, Irma Jiménez-Escobar, Carlos Jiménez-Gutiérrez, Gabriel López-Velazquez, Jordi Espadaler-Mazo
medRxiv 2021.05.20.21256954; doi: https://doi.org/10.1101/2021.05.20.21256954

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (141)
  • Cardiovascular Medicine (1960)
  • Dentistry and Oral Medicine (253)
  • Dermatology (186)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (702)
  • Epidemiology (11119)
  • Forensic Medicine (8)
  • Gastroenterology (629)
  • Genetic and Genomic Medicine (3193)
  • Geriatric Medicine (310)
  • Health Economics (566)
  • Health Informatics (2048)
  • Health Policy (864)
  • Health Systems and Quality Improvement (789)
  • Hematology (310)
  • HIV/AIDS (684)
  • Infectious Diseases (except HIV/AIDS) (12739)
  • Intensive Care and Critical Care Medicine (708)
  • Medical Education (318)
  • Medical Ethics (92)
  • Nephrology (337)
  • Neurology (3000)
  • Nursing (165)
  • Nutrition (465)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1560)
  • Ophthalmology (478)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (914)
  • Pharmacology and Therapeutics (383)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2795)
  • Public and Global Health (5610)
  • Radiology and Imaging (1100)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (764)
  • Rheumatology (341)
  • Sexual and Reproductive Health (314)
  • Sports Medicine (289)
  • Surgery (347)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (133)